Longstanding trend of mega-rounds continues as February sees billions channeled into companies advancing therapies for oncology, rare diseases, …
Longstanding trend of mega-rounds continues as February sees billions channeled into companies advancing therapies for oncology, rare diseases, …
The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
At ECCO 2025 in Berlin, Sanofi and Teva presented the first detailed findings from the RELIEVE UCCD study …
Roche introduces an ultra-rapid and scalable next-generation sequencing method poised to accelerate genomic research and potentially reshape clinical …
February 2025 sees a surge in large-scale biotech investments—from Eikon’s massive Series D to critical autoimmune and oncology …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
The 26th Clinical Trial Supply Europe conference (25–26 February, Barcelona) will showcase how AI, logistics innovation, and regulatory …
The FDA has approved Merilog (insulin-aspart-szjj), marking the first biosimilar to Novolog (insulin aspart), and widening affordable insulin …
The FDA has cleared vimseltinib (Romvimza), a first-in-class CSF1R inhibitor, for symptomatic tenosynovial giant cell tumor—marking a breakthrough …
The FDA has approved SPN-830 (Onapgo)—a novel subcutaneous apomorphine infusion device—offering continuous, effective management of motor fluctuations in …
